Establishment of the novel treatment strategy against urothelial carcinoma controlling for cancer stem-like property

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K11157
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: St. Marianna University School of Medicine (2019); Keio University (2017-2018)
• Principal Investigator: Kikuchi Eiji 聖マリアンナ医科大学, 医学部, 教授 (10286552)
• Co-Investigator(Kenkyū-buntansha): 小坂 威雄 慶應義塾大学, 医学部(信濃町), 講師 (30445407)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 尿路上皮癌 / 癌幹細胞 / 抗癌剤耐性 / シスプラチン

Outline of Final Research Achievements

The following five results were obtained. (1) High expression of CD44v9 in tumor specimen is a prognostic factor in patients with muscle invasive bladder cancer. (2) CD44v8-10 is highly associated with acquisition of resistance for anti-cancer agents in bladder cancer. (3) In current smoker bladder cancer patients high PD-1 expression in tumor nest is a prognostic factor (4) Metformin had cytotoxic effects against T24 cell line with high CD44v expression. (5) In mouse bladder cancer lung metastatic model, sulfasalazine plus cisplatin had strong anti-tumor effects.

Free Research Field

尿路上皮癌

Academic Significance and Societal Importance of the Research Achievements

尿路上皮癌におけるCD44v9、喫煙膀胱癌におけるPD-1は今後予後マーカーとしての確立が望まれる。このことにより予後不良症例の抽出、リスク分類が可能となり個別化治療への応用の意義が示唆される。CD44vは膀胱癌の抗癌剤耐性獲得に寄与し、CD44vをターゲットしたメトホルミンやサラゾスルファピリジンは次世代の新規治療戦略として期待されると考える。